Trial Profile
Efficacy and Long-term Safety of Oral Semaglutide Versus Sitagliptin in Subjects With Type 2 Diabetes
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 05 Jun 2023
Price :
$35
*
At a glance
- Drugs Semaglutide (Primary) ; Metformin; Sitagliptin
- Indications Type 2 diabetes mellitus
- Focus Registrational; Therapeutic Use
- Acronyms PIONEER 3
- Sponsors Novo Nordisk
- 31 May 2023 Results of a post-hoc analysis from clinical trials: PIONEER 1-5 and 8 assessing clinically relevant composite endpoints of HbA1c (glyclated haemogloblin) reduction published in the Diabetes Therapy
- 23 Sep 2022 Results of an exploratory analysis assessing time spent by patients with HbA1c <7.0% (53 mmol/mol), and likelihood of maintaining this glycaemic control using data from four clinical studies: PIONEER-2, PIONEER-3, PIONEER-4 and PIONEER-7 presented at the 58th Annual Meeting of the European Association for the Study of Diabetes.
- 12 May 2022 Results evaluating Cost-Effectiveness of Oral Semaglutide in Spain by deriving data from PIONEER 2, PIONEER 3 and PIONEER 4, published in the Advances in Therapy